News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genmab, Inc. (GNMSF.PK) Sells Arzerra Co-Promotion Rights to GlaxoSmithKline (GSK); Genmab will Receive a One-time Payment of $4.5M from GSK Upon the FDA's Acceptance for Review of the Filing of the First BLA for Ofatumumab


12/18/2008 11:41:20 AM

COPENHAGEN, Denmark, Dec. 18, 2008 (GLOBE NEWSWIRE) -- Summary: Genmab announces an amendment to its worldwide agreement with GSK to co-develop and commercialize Arzerra.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES